OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Holdings in Rezolute, Inc. (NASDAQ:RZLT)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 19.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 526,223 shares of the company's stock after acquiring an additional 86,990 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.91% of Rezolute worth $2,578,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of RZLT. Adage Capital Partners GP L.L.C. increased its position in shares of Rezolute by 699.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock valued at $12,377,000 after purchasing an additional 2,210,038 shares during the last quarter. Susquehanna International Group LLP grew its position in Rezolute by 749.0% in the 4th quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock valued at $4,379,000 after acquiring an additional 788,349 shares during the last quarter. Walleye Capital LLC bought a new position in Rezolute in the 4th quarter valued at $2,408,000. Nantahala Capital Management LLC grew its position in Rezolute by 10.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after acquiring an additional 280,861 shares during the last quarter. Finally, Integral Health Asset Management LLC grew its position in Rezolute by 100.0% in the 4th quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company's stock valued at $2,450,000 after acquiring an additional 250,000 shares during the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Rezolute

In other Rezolute news, Director Wladimir Hogenhuis purchased 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the director now owns 77,267 shares in the company, valued at $363,154.90. This represents a 14.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nevan C. Elam purchased 12,302 shares of the firm's stock in a transaction on Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the purchase, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. The trade was a 5.81% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 39,060 shares of company stock worth $130,694. 18.39% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RZLT has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Craig Hallum raised Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Wedbush reissued an "outperform" rating and set a $12.00 price target on shares of Rezolute in a research report on Wednesday. JMP Securities increased their price target on Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $12.14.

Rezolute Stock Up 2.0%

Shares of NASDAQ RZLT traded up $0.07 during mid-day trading on Thursday, reaching $3.56. 714,164 shares of the company were exchanged, compared to its average volume of 624,521. The stock has a market cap of $215.50 million, a price-to-earnings ratio of -2.92 and a beta of 1.01. Rezolute, Inc. has a 1 year low of $2.22 and a 1 year high of $6.19. The firm has a 50-day moving average of $3.24 and a 200 day moving average of $4.32.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, equities analysts forecast that Rezolute, Inc. will post -0.93 earnings per share for the current year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.